News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Capstone Therapeutics (CAPS) Announces Chrysalin(r) (TP508, Rusalatide Acetate) Scientific Abstracts to be Presented At the American Society for Cell Biology 48th Annual Meeting; Studies Characterize Integrin Interaction and Biologic Activity


12/15/2008 11:49:25 AM

TEMPE, Ariz., Dec. 15, 2008 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) announced today the publication of several abstracts characterizing the science of its novel thrombin peptide Chrysalin(r) (TP508 or rusalatide acetate). The abstracts being presented at the American Society for Cell Biology 48th Annual Meeting (December 13 - 17, 2008 - San Francisco, CA) provide new support for the mechanism of action and observed effects of TP508.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES